Roche presents ESMO cancer data: Roche Holding stock falls 1.70 percent

Published on 10/19/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche will show phase III cancer data at ESMO on October 23, 2026. Roche Holding stock costs EUR 408.13, 1.70 percent below the Xetra close.

Oncology data and reporting dates

Roche disclosed its ESMO 2026 program on October 19, 2026.
First-half 2026 revenue was CHF 31.50 billion, down 1.20 percent year over year.
Roche Holding stock trades at EUR 408.13 at 9:10 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.70 percent below the Xetra close of October 16, 2026.
Roche will present third-quarter sales on October 22, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 408.13 at Lang & Schwarz at 9:10 a.m. CEST on October 19, 2026, down 1.70 percent versus the Xetra close of October 16, 2026 at EUR 415.20. The company published its ESMO 2026 oncology program on October 19, 2026, with phase III data on divarasib, giredestrant and Tam-Peli, according to Roche.

Cancer pipeline takes center stage

The release puts divarasib at the center of the lung cancer program. Roche said phase III Krascendo 1 showed superior efficacy against first-generation KRAS G12C inhibitors in previously treated advanced non-small cell lung cancer.

The ESMO agenda also includes patient-reported outcomes from the phase III lidERA breast cancer trial and interim phase III results for Tam-Peli in recurrent or metastatic nasopharyngeal carcinoma. Roche will present the divarasib data in a late-breaking session on October 25, 2026, while giredestrant data are scheduled for October 23, 2026, according to the company release.

First-half figures frame the event

The pipeline update arrives ahead of Roche's next sales report. First-half 2026 revenue stood at CHF 31.50 billion, down 1.20 percent from the first half of 2025, while net income fell 7.30 percent to CHF 6.87 billion and the profit margin declined to 22.00 percent, according to Simply Wall St. The figures make the upcoming sales update important for judging whether pipeline progress is translating into operating growth.

What comes next for Roche?

Roche lists its third-quarter sales presentation for October 22, 2026 at 2:00 p.m. CEST in Basel. Its investor calendar also lists the Berenberg Pharma CFO Series for November 2, 2026 at 3:00 p.m. CET, according to Roche.

Before the sales update, JPMorgan kept a Neutral rating and a CHF 325.00 price target on October 11, 2026, according to Finanznachrichten. The target is stated in Swiss francs and is separate from the euro quotation.

The euro quote sets the tone

The Roche Holding stock price was 1.70 percent below the Xetra close as investors assessed the pipeline disclosure alongside the approaching sales report. The euro quote stood at EUR 408.13 at Lang & Schwarz on October 19, 2026 at 9:10 a.m. CEST, versus the Xetra close of EUR 415.20 on October 16, 2026. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.